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Abstract
Background: Toll-like receptors (TLRs) have garnered an extraordinary amount of interest in cancer research due to
their role in tumor progression. By activating the production of several biological factors, TLRs induce type I
interferons and other cytokines, which drive an inflammatory response and activate the adaptive immune system.
The aim of this study was to investigate the expression and clinical relevance of TLR3, 4 and 9 in breast cancer.
Methods: The expression levels of TLR3, TLR4 and TLR9 were analyzed on tumors from 74 patients with breast
cancer. The analysis was performed by immunohistochemistry.
Results: Samples of carcinomas with recurrence exhibited a significant increase in the mRNA levels of TLR3, TLR4
and TLR9. Tumors showed high expression of TLRs expression levels by cancer cells, especially TLR4 and 9.
Nevertheless, a significant percentage of tumors also showed TLR4 expression by mononuclear inflammatory cells
(21.6%) and TLR9 expression by fibroblast-like cells (57.5%). Tumors with high TLR3 expression by tumor cell or with
high TLR4 expression by mononuclear inflammatory cells were significantly associated with higher probability of
metastasis. However, tumours with high TLR9 expression by fibroblast-like cells were associated with low
probability of metastasis.
Conclusions: The expression levels of TLR3, TLR4 and TLR9 have clinical interest as indicators of tumor
aggressiveness in breast cancer. TLRs may represent therapeutic targets in breast cancer.
Background
Breast cancer remains a major cause of death in women
in the developed world. One in nine women will suffer
from breast cancer during her life [1]. Although clinical
signs of disseminated disease occur in fewer than 10%
of women at the time of diagnosis, the disease relapses
in the form of metastasis within 5 years of surgery in
about half of apparently localized tumours. It is difficult
to predict the occurrence of distant metastases since
breast cancer is a heterogeneous disease encompassing
complex pathologic entities. For all of these reasons,
new prognostic factors are essential to improving the
classic risk classification in breast cancer.
Inflammation and cancer are related [2-8]. It is well
known that persistent inflammatory conditions can
induce cancer formation. This is in part, because
cytokines and chemokines play a crucial role promoting
angiogenesis, metastasis, and subversion of adaptive
immunity [9].
Toll-like receptors (TLRs) are considered a link
between innate (non-specific) and adaptive (specific)
immunity and TLRs contribute to the immune system’s
capacity to efficiently combat pathogens [10]. This is
done by means of the induction of signaling cascades
resulting in the induction of type I interferons (IFNs)
and other cytokines. The result of this process leads to
an inflammatory response and activates the adaptative
immune system [11]. TLRs also enable immune cells to
discriminate between self and nonself antigens [12]. As
molecular sensors, TLRs detect pathogen-derived pro-
ducts and trigger protective responses. These responses
include the secretion of cytokines that increase the resis-
tance of infected cells as well as the release of chemo-
kines that recruit immune cells to dead cells, thus
limiting microbe spreading.* Correspondence: investigacion@hospitaldejove.com1Unidad de Investigación, Fundación Hospital de Jove, Gijón, Spain
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Viral dsRNA participates in virus-infected cell apopto-
sis, but the signaling pathway involved remains unclear.
Salaun et al. [13] showed that synthetic dsRNA induce
apoptosis of human breast cancer cells in a TLR3-
dependent manner. This mechanism involves the mole-
cular adaptor Toll/IL-1R domain-containing adapter
inducing IFN- and type I IFN autocrine signaling, but
occurs independently of the dsRNA-activated kinase.
The role of TLRs expressed by tumor cells in the eva-
sion of immune surveillance was demonstrated in ani-
mal experiments [14]. These results showed that TLRs
stimulation may lead to tumor progression and that
there are now means to specifically reverse this
unwanted effect.
The purpose of the present study was to investigate
the expression of TLR3, TLR4 and TLR9 in breast can-
cer as well as its relation to distant metastasis. To
address these questions, we analyzed the protein levels
of TLR3, TLR4 and TLR9 by tissue arrays technology
(TA) and immunohistochemical techniques, and their
mRNA levels by real time-PCR.
Methods
Patients
This study included 74 women with histologically con-
firmed early breast cancer confirmed and treated
between 1990 and 2003. We selected patients with the
following inclusion criteria: invasive ductal carcinoma,
in cases of non-recurrence, patients had been followed-
up for a minimum of 5 years of follow-up. The exclu-
sion criteria were the following: metastatic disease at
presentation, prior history of any kind of malignant
tumor, bilateral breast cancer at presentation, any type
of neoadjuvant therapy, development of loco-regional
recurrence during the follow-up period, development of
a second primary cancer, and absence of sufficient tissue
in paraffin blocks. From a total of 1,264 patients fulfill-
ing these criteria, we randomly selected a sample size of
74 patients in accordance divided them into two differ-
ent groups of similar size and stratified each group with
regard to the development of metastasis. Patients and
tumor characteristics are listed in Table 1. Patients were
treated according to approved guidelines at our institu-
tion. The study adhered to national regulations and was
approved by our institutions Ethics and Investigation
Committee. Tissue samples were obtained prior
informed consent from the patients. All patients were
followed for distant metastasis status by clinical and bio-
logical studies every 3 months for the first 2 years and
then yearly. Radiological studies were performed yearly,
or when considered necessary. The end-point was dis-
tant metastatic relapse. The median follow-up period
was 85 months in patients without metastases, and 46
months in patients with metastases.
Tissue array immunohistochemistry and analysis
Breast carcinoma tissue samples were obtained at the
time of surgery. All specimens were routinely fixed in
10% neutral buffered formalin and stored in paraffin at
room temperature for a period of four months to five
years before further testing. Histopathological represen-
tative tumor areas were defined on haematoxylin and
eosin-stained sections and marked on the slide. Tumour
tissue array (TA) blocks were obtained by punching a
tissue cylinder (core) with a diameter of 1.5 mm
through a histological representative area of each ‘donor’
tumor block, which was then inserted into an empty
‘recipient’ TA paraffin block using a manual tissue
arrayer (Beecher Instruments, Sun Prairie, Winconsin,
USA) as described elsewhere [15]. Collection of tissue
cores was carried out under highly controlled condi-
tions. Two cores were employed for each case.
Four composite high-density TA blocks were designed,
and serial 5-μm sections were consecutively cut with a
microtome (Leica Microsystems GmbH, Wetzlar,
Germany) and transferred to adhesive-coated slides.
One section from each TA block was stained with hae-
matoxylin and eosin, and these slides were then
reviewed to confirm that the sample was representative
of the original tumor. Immunohistochemistry was done
on these sections of TA fixed in 10% buffered formalin
and embedded in paraffin using a TechMate TM50
autostainer (Dako, Glostrup, Denmark). Monoclonal
antibodies for TLR3 (TLR3.7; ref: sc-32232), TLR4 (H-
80; sc-10741), and TLR9 (H-100; sc-25468) were
obtained from Santa Cruz Biotechnology (California,
USA). The dilution for each antibody was established
based on negative and positive controls (1/50 for TLR3,
1/100 for TLR4 and TLR9).
Tissue sections were deparaffinized in xylene, and
then rehydrated in graded concentrations of ethyl alco-
hol (100%, 96%, 80%, 70% and water). To enhance anti-
gen retrieval for the three antibodies, TA sections were
microwave-treated (H2800 Microwave Processor, EBS-
ciences, East Granby, Connecticut, USA) in citrate buf-
fer, (Target Retrieval Solution, Dako), with high pH
(pH9) for TLR3 and low pH (pH6) for TLR4 and 9, at
99°C for 16 min. Endogenous peroxidase activity was
blocked by incubating the slides in peroxidase-blocking
solution (Dako) for 5 min. The EnVision Detection Kit
(Dako) was used as the staining detection system. Sec-
tions were counterstained with haematoxylin, dehy-
drated with ethanol, and permanently coverslipped.
The location of immunoreactivity, percentage of
stained cells, and intensity were determined for each
antibody preparation. All the cases were semiquantified
for each protein-stained area. An image analysis system
using the Olympus BX51 microscope and analysis soft
(analySIS®, Soft imaging system, Münster, Germany) was
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Table 1 Basal characteristics of 74 patients with invasive carcinoma of the breast
CHARACTERISTICS WITHOUT RECURRENCE N(%) WITH RECURRENCE N(%)
Age (years)
<57 14 (48.2) 29 (64.4)
>57 15 (51.8) 16 (35.6)
Menopausal status
Premenopausal 11 (37.9) 11 (24.4)
Postmenopausal 18 (62.1) 34 (75.6)
Tumoral size
T1 14 (48.2) 15 (33.3)
T2 15 (51.8) 30 (66.7)
Nodal status
N- 14 (48.2) 22 (48.8)
N+ 15 (51.8) 23 (51.2)
Histological grade
Well dif 11 (37.9) 10 (22.2)
Mod dif 15 (51.7) 20 (44.4)
Poorly dif 3 (10.4) 15 (33.4)
Nottingham pronostic index
<3.4 10 (34.4) 12 (26.7)
3.4-5.4 16(55.1) 21 (46.6)
>5.4 3 (10.5) 12 (26.7)
Estrogen receptors
Negative 10 (34.4) 28 (62.8)
Positive 19 (65.6) 17 (37.8)
Progesterone receptors
Negative 11 (37.9) 32 (71,1)
Positive 18 (62.1) 13 (28,9)
Desmoplasia
Negative 11 (37.9) 11 (24.4)
Positive 18 (62.1) 34 (75.5)
Peritumoral inflammation
No 15 (51.7) 20 (44.4)
Mild 13 (44.8) 24 (53.3)
Intense 1 (3.5) 1 (2.3)
Tumor progress
Expansive 16 (55.1) 17 (37.7)
Infiltrating 13 (44.9) 28 (62.3)
Mitosis
<10 16 (55.1) 18 (40)
>10 13 (44.9) 27 (60)
Tumoral necrosis
No 26 (89.6) 37 (82.2)
Focal 2 (6.9) 7 (15.5)
Extense 1 (3.5) 1 (2.3)
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employed as follows: tumor sections were stained with
antibodies according to the method explained above and
counterstained with haematoxylin. There were different
optical thresholds for both stains. Each core was
scanned with a 400× power objective in two fields per
core. Fields were selected on the basis of protein-stained
areas. The computer program selects and traces a line
around antibody-stained areas (red spots) for higher
optical threshold. The remaining non-stained areas (hae-
matoxylin-stained tissue with lower optical threshold)
appear as a blue background. Each field has an area
ratio of stained (red) versus non-stained areas (blue).
A final area ratio was obtained after averaging two
fields. To evaluate immunostaining intensity we used a
numeric score ranging from 0 to 3, reflecting the
intensity as follows: 0, no staining; 1, weak staining; 2,
moderate staining; and 3, intense staining. Using an
Excel spreadsheet, the mean score was obtained by mul-
tiplying the intensity score (I) by the percentage of
stained cells [16] and the results were added together
(total score: I × PC). This overall score was then aver-
aged with the number of cores that were done for each
patient. If there was no tumor in a particular core, then
no score was given. In addition, for each tumor, the
mean score of two core biopsies was calculated.
Western blot
Samples were separated by SDS-PAGE using 10% polya-
crylamide gels and run at constant 120 V (Mini-Protean®
Tetra Electrophoresis System, Bio-Rad, Hercules, USA).
The tetraprotean transference kit was used to electro-
transfer proteins to nitrocellulose membranes at 160
mA for 1 h in transfer buffer (0.248 M Tris pH 8.8, 1.92
M glycine and 20% methanol). The nitrocellulose filters
containing the transferred proteins were blocked by
rocking for 1 h in Tris-buffered saline (TBS) contained
1% skimmed milk and rinsed 3 tines in TBS. The filters
were incubated for 2 h at room temperature with one of
these monoclonal antibodies: anti-TLR3 (ref: sc-32232),
anti-TLR4 (sc-10741), anti-TLR9 (sc-25468) (Santa Cruz
Biotechnology, California, USA) diluted in TBS contain-
ing 1% skimmed milk. The blots were then washed with
TBS, incubated with protein A peroxidase and the reac-
tive protein bands were visualized by chemiluminiscence
(Pierce ECL Western Blotting Substrate, Rockford,
USA).
Real-time PCR
Total RNA was isolated from breast tissue using the
RNeasy Mini kit (Quiagen, Hilden, Germany), including
DNase treatment. The integrity of the eluted total RNA
was checked by agarose gel electrophoresis and the RNA
concentration was determined spectrophotometrically.
First strand cDNA was made using the High Capacity
cDNA Reverse Transcrition kit (Applied Byosystems,
Cheshire, UK) following the manufacturer’s instructions.
The reverse transcription step was carried using the fol-
lowing program: 25°C for 10 min, 37°C for 120 min and
85°C for 5 sec. The expression levels of TLR3, TLR4,
TLR9 and b-actin were assessed by real-time PCR using
ABI Prism 7900 HT thermocycler (Applied Biosystems,
Cheshire, UK) and the Fast SYBR Green Master
Mix (Applied Biosystems, Cheshire, UK) with the follow-
ing cycling conditions: 95°C for 20 sec, 40 cycles of 95°C





3’ (reverse) for TLR4, 5’-CTTCCCTGTAGCTGCTG
TCC-3’ (forward) and 5’-CCTGCACCAGGAGAGACAG-
3’ (reverse) for TLR9 and 5’-GGCACCCAGCACAAT
GAAG-3’ (forward) and 5’-CCGATCCACACGGAG-
TACTTG-3’ (reverse) for b-actin. PCR products were
separated on 2% agarose gels containing ethidium bro-
mide (0.5 μg/ml).
Data analysis and statistical methods
Differences in percentages were calculated with the chi-
square test. Immunostaining score values for each pro-
tein were expressed as median (range). A comparison of
group immunostaining values was made with the Mann-
Whitney or Kruskal-Wallis tests. For metastasis-free sur-
vival analysis we used the Cox’s univariate method.
Cox’s regression model was used to examine interac-
tions of different prognostic factors in a multivariate
analysis. The SPSS 17.0 program was used for all
calculations.
Results
In the present study, we investigated the expression
levels of TLR3, TLR4 and TLR9 in tumors from 74
women with ductal invasive breast cancer. Figure 1
shows examples of immunostaining for these proteins.
TLRs showed an intracellular location pattern, but
A B C 
Figure 1 Examples of immunostaining for TLRs analyzed: A)
TLR3 positive staining for tumor cell. 200× B) TLR4 positive
staining for tumor cell and mononuclear inflammatory cells. 400×,
and C) TLR9 positive staining for tumor cell and fibroblast-like cells.
200×.
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TLR3 also was localized in the cell surface. Positive
staining was generally found in cancer cells but also in
some stromal cells (fibroblast-like cells as well as in
mononuclear inflammatory cells -MICs-). Table 2
sumarizes the percentages of each TLR staining in each
cellular type. In tumors, cancer cells exhibited high
expressions, especially of TLR4 and TLR9. Nevertheless,
a significant percentage of tumors also showed expres-
sion levels of TLR4 by MICs (21.6%) and of TLR9 by
fibroblast-like cells (57.5%).
The presence of the TLR gene products was con-
firmed by western blot in breast tumor samples (Figure
2). The results clearly showed immunoreactive bands
corresponding to TLR3, TLR4 and TLR9. As shown in
Figure 2 anti-TLR3, anti-TLR4 and anti-TLR9 recog-
nized bands of approximately 110, 100 and 120 KDa,
respectively.
Figure 3 shows the results of real time PCR. The per-
centage of TLR cDNA expression in samples obtained
from breast cancer patients with recurrence and from
breast cancer patients without recurrence are compared
in the upper panel whereas the electrophoresis analysis
is shown in the lower panel. We found elevated TLR
expression levels in tissue samples from patients with
recurrence relative to samples from patients without
recurrence.
Figure 4 shows the immunostaining score values,
which ranged widely for each TLR. We also evaluated
the possible relationship between the TLRs expressions
and clinicopathological factors of breast carcinomas
including menopausal status, tumor size, nodal status,
tumor stage, histological grade, estrogen and progester-
one receptors, tumor advancing edge, peri-tumor
inflammation and tumor necrosis as summarized in
Table 3. Both TLR3 and TLR4 expressions were signifi-
cantly and positively associates with tumor size. A sig-
nificant association between TLR3 or TLR9 expression
score and tumor stage was also found. In addition,
when compared with tumors from premenopausal
women, we found that tumors from postmenopausal
Table 2 TLRs expression in 74 cases of breast cancer










TLR3 52 (79) 2 (3) 2 (3)
TLR4 70 (95) 6 (8) 16 (22)
TLR9 73 (100) 42 (58) 5 (7)
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Figure 2 Representative western blots of immunoreactive toll-
like receptors (TLRs). Twenty micrograms of whole cell extract
from human breast carcinoma with (R) and without recurrence (WR)
were subject to 10% SDS-PAGE and transferred into a nitrocellulose
membrane and then immunolabelled with TLR3, TLR4, TLR9 and
b-actin (used as loading control) antiserum.
Figure 3 TLR3, 4 and 9 gene expression measured by
semiquantitative real time PCR in breast carcinomas. Upper
panel (A), shows the percentage of TLRs expression in recurrence
samples and without recurrence ones (WR). Lower panel,(B) shows
the electrophoresis bands after real time-PCR performed on equal
amounts of cDNA from each sample. The housekeeping used was


















Figure 4 the immunostaining score values for TLR3,4 and 9 in
breast carcinomas.
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women had significantly higher TLR3 and TLR4 score
values (Table 3).
We also analyzed the possible relationship between
TLRs immunostaining values and distant relapse-free
survival. Univariate analysis (Figure 4) demonstrated
that high score values for TLR3 expression, TLR3
expression by tumoral cells, or TLR4 expression by
MICs, were significantly associated with a great rate of
distant metastasis. However, TLR9 expression by
fibroblast-like cells was significantly associated with
low rate of distant metastases (Table 4 and Figure 5).
Multivariate analysis with a Cox model demonstrated
that tumour stage and progesterone receptor-status
were significantly and independently associated with
relapse-free survival in patients with breast cancer.
However, this same analysis also demonstrated that
TLRs expressions are significantly associated with
prognosis (Table 4).
Table 3 stadistical analysis between TLRs expressions and clinicopathological factors in women with breast
carcinomas
Characteristics TLR3 TLR4 TLR9
median (range) p median (range) p median (range) p
Menopausal Status
Premenopausal 51.4 (0-158) 0.048 57.37 (0-160) 0.006 138.7 (46-268) 0.319
Postmenopausal 65.9 (0-166) 72.33 (0-158) 153 (37-272)
Tumoral size
T1 49.7 (0-166) 0.005 62.7 (0-160) 0.039 140.2 (37-272) 0.269
T2 69.2 (0-162) 71.2 (38-158) 151.4 (46-268)
Nodal status
N- 60.5 (0-162) 0.717 68 (0-143) 0.725 147.5 (38-246) 0.724
N+ 60.5 (0-166) 68.7 (36-160) 153 (46-272)
Estrogen receptors
Negative 63.7 (0-166) 0.923 67.1 (0-159) 0.436 150.5 (46-272) 0.904
Positive 59.9 (0-162) 69.4 (0-156.2) 148 (37-268)
Progesterone receptors
Negative 67.3 (0-166) 0.101 70 (0-158) 0.396 150.3 (46-272) 0.251
Positive 57.1 (0-158) 62.8 (38-135) 137.4 (37-268)
Tumoral progess
Expansive 62.7 (0-162) 0.863 71.6 (0-160) 0.247 151.8 (65-272) 0.167
Infiltrating 59.9 (0-166) 62.1 (0-156) 143.1 (38-268)
Stage
I 46 (0-70) 0.024 62.8 (0-135) 0.175 136.9 (37-180) 0.035
II 62.4 (0-162) 69.3 (38-160) 155.9 (46-268)
III 72.3 (0-166) 69 (36-158) 147.5 (60-272)
SBR
SBRI 57.1 (0-102) 0.671 62.8 (0-135) 0.201 137.9 (38-272) 0.218
SBRII 57.9 (0-166) 66.5 (0-160) 148.4 (60-246)
SBRIII 64.3 (0-158) 96.2 (0-158) 161.7 (46-268)
Peritumoral inflamation
No 57.9 (0.162) 0.815 67.5 (0-156) 0.815 141.7 (37-272) 0.191
Mild 61 (0-166) 69.4 (0-160) 158,2 (46-268)
Intense 60 (50-70) 88.4 (62-114) 137.7 (115-159)
Tumoral necrosis
No 57.5 (0-166) 0.359 68 (0-158) 0.184 147.5 (38-272) 0.095
Focal 69.7 (0-162) 64.4 (46-125) 151.1 (119-173)
Extense 71.4 (29-113) 133.2 (106-160) 214.6 (183-246)
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Discussion
This study analyzes tumor expression as well as the
prognostic significance of TLRs in breast cancer. The
results demonstrated an association TLR3, TLR4 and
TLR9 expression and distant metastasis.
TLRs expression has been described in different
human tumors [13,17-28]. Receptor-deficient mice were
found to be protected from or develop less inducible
tumors in experimental models [22,29]. Cancer cells
activated by TLR signals may release cytokines and che-
mokines that in turn may recruit immune cells and sti-
mulate them to release further cytokines and
chemokines. This process results in a cytokine profile
that is associated with immune tolerance, cancer pro-
gression and propagation of the tumor microenviron-
ment [30]. Recent evidences also show that functional
TLRs may play an important role in tumor progression
by activating the production of interleukins, tumor-
necrosis factor-alpha (TNF-a), nuclear factor-kappaBeta
(NF-kappaB) and metalloproteases [31,32]. Likewise,
activation of tumor cell TLRs not only promotes tumor
cell proliferation and resistance to apoptosis, but also
enhances tumor cell invasion and metastasis by regulat-
ing metalloproteases and integrins [33-35]. Although
expression of these factors was generally associated with
an adverse prognosis, the expression pattern of TLRs in
human breast cancer tissues is largely unknown. Our
results show high expression of TLR3, TLR4 and TLR9
by breast cancer cells though.
Our results showed that TLR3 expression is associated
with high probability of metastasis, which is in agree-
ment with previous studies indicating that TLR3 expres-
sion is related to tumoral aggressiveness [13,36-39].
Therefore, TLR3 may represent a good therapeutic tar-
get in breast cancer. In this sense, there are studies
showing a variable antineoplastic effect caused by a
blockade of TLR3 [40,41].
The TLR4 expression by MICs and/or TLR9 by fibro-
blast-like cells is another interesting finding of our
study. TLR4 expression by MICs was associated with an
increased incidence of metastasis, whereas TLR9 expres-
sion by fibroblast-like cells was associated a low metas-
tasis-rate. These findings support data from other
authors on the importance of the tumor stromal cells in
tumor behavior. The role of stromal cells has been
attributed to the release by them of various extracellular
matrix proteins, growth factors, proteases and other fac-
tors that act as signal transducers for tumor progression
[42-52]. Therefore, our results also suggest the existence
of different phenotypes of stromal cells that influence
prognosis depending on their TLR expression pattern.
TLR4 recognizes several bindings which in turn activate
transcription factors, resulting in the expression and
release of cytokines such as interleukin-1, interleukin-6
Table 4 Cox’s univariate (HR) and multivariate (RR) analysis of the relationship between TLRs expression and
relapse-free survival
Factor Number of patients Event frequency HR (95% CI) RR (95% CI)
TLR3
Score<median>median 33/33 13/28 3.4 (1.8-6.7)** 2.6 (1-3-5.1)**
CT (-) vs (+) 14/52 may-36 2.8 (1.1-7.2)* 2.5 (0-9-6.5)*
TLR4
MIC (-) vs (+) 58/16 29/16 3.7 (2-7)** 3.5 (1.8-6.8)**
TLR9
F (-) vs (+) 31/42 24/21 0.4 (0.2-0.7)** 0.3 (0.3-0.6)**
Tumoral stage II vs III 38/20 20/17 1.9 (1.3-3) ** 2.8 (1.2-6.5)*
Progesterone receptors positive vs negative 42/30 31/13 0.4 (0.2-0.8)* 0.3 (0.1-0.7)**
*p < 0.005; **p < 0.05
Figure 5 A) Probability of biochemical recurrence as function
of TLR3 median (p:0.0001), B) probability of biochemical
recurrence as function of TLR3 expression by tumor cells (p:
0.022). C) probability of biochemical recurrence as function of TLR4
in monocites (p: 0001) and D) probability of biochemical recurrence
as function of TLR9 expression by intratumor fibroblasts (p: 0.003).
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and interleukin-8 [53]. Consequently, considering the fact
that the TLR4 expression by MICs is increased in breast
cancer cases with recurrence, our results suggest that the
use of TLR4 agonists may become a useful anticancer
strategy [18,54,55].
Our data also suggest that TLR9 may help to identify
one population of fibroblast-like cells associated with
good prognosis. Although the biological significance of
TLR9 expression by stromal fibroblast-like cells is cur-
rently unknown, there are data pointing to a protective
role of this receptor against tumoral progression.
Indeed, it was demonstrated that stimulation of TLR-9
activates human plasmacytoid dendritic cells and B cells,
thus inducing potent innate immune responses in pre-
clinical tumor models as well as in patients [56]. It is
therefore understandable that using bindings of nucleic
acid-sensing TLR9 as a pharmacological intervention in
various diseases is gaining in interest.
Conclusions
Our results show that TLR expression have prognostic
significance and suggest that these markers may repre-
sent new therapeutic targets in breast cancer. Further
studies on the TLRs expression in tumor context may
help to better understand the process that links inflam-
mation and cancer, as well as to assess the biological
and clinical importance of the interplay between tumor
and stroma in breast cancer.
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